Perennial Investment Advisors LLC Makes New $645,000 Investment in Vertex Pharmaceuticals Incorporated $VRTX

Posted by Brian Himes on Aug 27th, 2026

Perennial Investment Advisors LLC acquired a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,300 shares of the pharmaceutical company’s stock, valued at approximately $645,000.

A number of other hedge funds have also recently made changes to their positions in VRTX. BlackRock Inc. purchased a new stake in shares of Vertex Pharmaceuticals in the second quarter valued at about $11,975,849,000. Norges Bank bought a new position in shares of Vertex Pharmaceuticals during the 4th quarter worth approximately $1,440,149,000. Bank of America Corp DE bought a new position in shares of Vertex Pharmaceuticals in the second quarter valued at approximately $1,509,651,000. AIGH Capital Management LLC purchased a new stake in shares of Vertex Pharmaceuticals during the second quarter valued at approximately $26,725,000. Finally, Solas Capital Management LLC purchased a new stake in shares of Vertex Pharmaceuticals during the 2nd quarter valued at $20,311,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Price Performance

VRTX opened at $547.29 on Thursday. Vertex Pharmaceuticals Incorporated has a one year low of $374.17 and a one year high of $555.69. The business has a 50 day simple moving average of $498.36 and a two-hundred day simple moving average of $467.66. The firm has a market capitalization of $138.90 billion, a price-to-earnings ratio of 31.86, a PEG ratio of 2.40 and a beta of 0.30.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The pharmaceutical company reported $4.73 earnings per share for the quarter, missing analysts’ consensus estimates of $4.74 by ($0.01). The business had revenue of $3.33 billion during the quarter, compared to the consensus estimate of $3.23 billion. Vertex Pharmaceuticals had a return on equity of 23.09% and a net margin of 35.00%.Vertex Pharmaceuticals’s quarterly revenue was up 12.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $4.52 earnings per share. As a group, sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post 16.86 EPS for the current fiscal year.

Analysts Set New Price Targets

VRTX has been the topic of a number of research reports. UBS Group lifted their price target on shares of Vertex Pharmaceuticals from $545.00 to $585.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Stifel Nicolaus set a $500.00 price target on Vertex Pharmaceuticals in a research report on Tuesday, August 4th. Cantor Fitzgerald raised their price objective on shares of Vertex Pharmaceuticals from $590.00 to $595.00 and gave the stock an “overweight” rating in a report on Tuesday, August 4th. Royal Bank Of Canada lifted their target price on Vertex Pharmaceuticals from $543.00 to $570.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. Finally, Weiss Ratings cut shares of Vertex Pharmaceuticals from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, Vertex Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $563.50.

Get Our Latest Research Report on Vertex Pharmaceuticals

Insider Activity at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, CMO Carmen Bozic sold 596 shares of the company’s stock in a transaction on Friday, June 26th. The shares were sold at an average price of $482.50, for a total value of $287,570.00. Following the completion of the transaction, the chief marketing officer directly owned 15,337 shares in the company, valued at approximately $7,400,102.50. This represents a 3.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Duncan Mckechnie sold 1,541 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $519.00, for a total transaction of $799,779.00. Following the completion of the sale, the executive vice president directly owned 11,001 shares of the company’s stock, valued at approximately $5,709,519. This represents a 12.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 10,464 shares of company stock worth $4,959,397 over the last quarter. Corporate insiders own 0.20% of the company’s stock.

About Vertex Pharmaceuticals

(Free Report)

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.